A focus on intra-abdominal infections

World Journal of Emergency Surgery

Volumn 5, Issue 1, 2010, Pages

  Sartelli, Massimo ^a  

^a MACERATA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649961917     PISSN: None     EISSN: 17497922     Source Type: Journal    
DOI: 10.1186/1749-7922-5-9     Document Type: Review

References (198)

1. Menichetti F, Sganga G. Definition and classification of intra-abdominal infections. J Chemother 2009, 21(Suppl 1):3-4.
2. Malangoni MA, Inui T. Peritonitis - the Western experience. World J Emerg Surg 2006, 1:25. 10.1186/1749-7922-1-25, 1592073, 16953882.
3. Schoeffel U, Jacobs E, Ruf G, Mierswa F, von Specht BU, Farthmann EH. Intraperitoneal micro-organisms and the severity of peritonitis. Eur J Surg 1995, 161:501-508.
4. Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicentre study. Peritonitis Study Group. Langenbecks Arch Surg 1999, 384:24-32. 10.1007/s004230050169, 10367626.
5. Mulier S, Penninckx F, Verwaest C, Filez L, Aerts R, Fieuws S, Lauwers P. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World J Surg 2003, 27:379-384. 10.1007/s00268-002-6705-x, 12658477.
6. Pieracci FM, Barie PS. Management of severe sepsis of abdominal origin. Scand J Surg 2007, 96(3):184-196.
7. Mulari K, Leppäniemi A. Severe secondary peritonitis following gastrointestinal tract perforation. Scand J Surg 2004, 93(3):204-208.
8. Horiuchi A, Watanabe Y, Doi T, Sato K, Yukumi S, Yoshida M, Yamamoto Y, Sugishita H, Kawachi K. Evaluation of prognostic factors and scoring system in colonic perforation. World J Gastroenterol 2007, 13(23):3228-3231.
9. Evans HL, Raymond DP, Pelletier SJ, Crabtree TD, Pruett TL, Sawyer KG. Tertiary peritonitis (recurrent diffuse or localized disease) is not an independent predictor of mortality in surgical patients with intra-abdominal infection. Surg Infect 2001, 2:255-265.
10. McLauchlan GJ, Anderson ID, Grant IS, Fearon KCH. Outcome of patients with abdominal sepsis treated in an intensive care unit. Br J Surg 1995, 82:524-529. 10.1002/bjs.1800820429, 7613902.
11. Koperna T, Schulz F. Prognosis and treatment of peritonitis: Do we need new scoring systems?. Arch Surg 1996, 131:180-186.
12. Pacelli F, Doglietto GB, Alfieri S, Piccioni E, Sgadari A, Gui D, Crucitti F. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg 1996, 131:641-645.
13. Ohmann C, Yang Q, Hau T, Wacha H, . the Peritonitis Study Group of the Surgical Infection Society Europe Prognostic modelling in peritonitis. Eur J Surg 1997, 163:53-60. the Peritonitis Study Group of the Surgical Infection Society Europe.
14. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996, 23:486-494.
15. Koperna T, Semmler D, Marian F. Risk stratification in emergency surgical patients: is the APACHE II score a reliable marker of physiological impairment?. Arch Surg 2001, 136(1):55-59. 10.1001/archsurg.136.1.55, 11146778.
16. Billing A, Fröhlich D, Schildberg FW. Prediction of outcome using the Mannheim peritonitis index in 2003 patients. Br J Surg 1994, 81:209-213. 10.1002/bjs.1800810217, 8156338.
17. Panhofer P, Izay B, Riedl M, Ferenc V, Ploder M, Jakesz R, Götzinger P. Age, microbiology and prognostic scores help to differentiate between secondary and tertiary peritonitis. Langenbecks Arch Surg 2009, 394(2):265-271. 10.1007/s00423-008-0301-y, 18343942.
18. Inui T, Haridas M, Claridge JA, Malangoni MA. Mortality for intra-abdominal infection is associated with intrinsic risk factors rather than the source of infection. Surgery 2009, 146(4):654-661. 10.1016/j.surg.2009.06.051, 19789024.
19. Emmi V, Sganga G. Diagnosis of intra-abdominal infections: Clinical findings and imaging. Infez Med 2008, 16(Suppl 1):19-30.
20. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidlines for the use of innovative therapies in sepsis. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
21. Puylaert JB, Zant FM, Rijke AM. Sonography and the acute abdomen: practical considerations. Am J Roentgenol 1997, 168(1):179-86.
22. Emmi V, Sganga G. Clinical diagnosis of intra-abdominal infections. J Chemother 2009, 21(Suppl 1):12-8.
23. Foinant M, Lipiecka E, Buc E, Boire JY, Schmidt J, Garcier JM, Pezet D, Boyer L. Impact of computed tomography on patient's care in non-traumatic acute abdomen: 90 patients. J Radiol 2007, 88(4):559-566. 10.1016/S0221-0363(07)89855-6, 17464254.
24. Doria AS, Moineddin R, Kellenberger CJ, Epelman M, Beyene J, Schuh S, Babyn PS, Dick PT. US or CT for diagnosis of appendicitis in children and adults? A meta-analysis. Radiology 2006, 241:83-94. 10.1148/radiol.2411050913, 16928974.
25. Peris A, Matano S, Manca G, Zagli G, Bonizzoli M, Cianchi G, Pasquini A, Batacchi S, Di Filippo A, Anichini V, Nicoletti P, Benemei S, Geppetti P. Bedside diagnostic laparoscopy to diagnose intraabdominal pathology in the intensive care unit. Crit Care 2009, 13(1):R25. 10.1186/cc7730, 2688143, 19243621.
26. Stefanidis D, Richardson WS, Chang L, Earle DB, Fanelli RD. The role of diagnostic laparoscopy for acute abdominal conditions: an evidence-based review. Surg Endosc 2009, 23:16-23. 10.1007/s00464-008-0103-x, 18814014.
27. Agresta F, Ciardo LF, Mazzarolo G, Michelet I, Orsi G, Trentin G, Bedin N. Peritonitis: laparoscopic approach. World J Emerg Surg 2006, 24(1):9.
28. Warren O, Kinross J, Paraskeva P, Darzi A. Emergency laparoscopy - current best practice. World World J Emerg Surg 2006, 31(1):24.
29. Golash V, Willson PD. Early laparoscopy as a routine procedure in the management of acute abdominal pain: A review of 1,320 patients. Surg Endosc 2005, 19(7):882-885. 10.1007/s00464-004-8866-1, 15920682.
30. Reiertsen O, Rosseland AR, Hoivik B, Solheim K. Laparoscopy in patients admitted for acute abdominal pain. Acta Chir Scand 1985, 151(6):521-524.
31. Majewski WD. Long-term outcome, adhesions, and quality of life after laparoscopic and open surgical therapies for acute abdomen: Follow-up of a prospective trial. Surg Endosc 2005, 19(1):81-90. 10.1007/s00464-003-9333-0, 15529189.
32. Azzarello G, Lanteri R, Rapisarda C, Santangelo M, Racalbuto A, Minutolo V, Di Cataldo A, Licata A. Ultrasound-guided percutaneous treatment of abdominal collections. Chir Ital 2009, 61(3):337-340.
33. Gazelle GS, Mueller PR. Abdominal abscess: Imaging and intervention. Radiol Clin North Am 1994, 32:913-932.
34. VanSonnenberg E, Ferrucci JT, Mueller PR, Wittenberg J, Simeone JF. Percutaneous drainage of abscesses and fluid collections: Technique, results, and applications. Radiology 1982, 142:1-10.
35. Bouali K, Magotteaux P, Jadot A, Saive C, Lombard R, Weerts J, Dallemagne B, Jehaes C, Delforge M, Fontaine F. Percutaneous catheter drainage of abdominal abscess after abdominal surgery: Results in 121 cases. J Belg Radiol 1993, 76:11-14.
36. VanSonnenberg E, Wing VW, Casola G, Coons HG, Nakamoto SK, Mueller PR, Ferrucci JT, Halasz NA, Simeone JF. Temporizing effect of percutaneous drainage of complicated abscesses in critically ill patients. Am J Roentgenol 1984, 142:821-826.
37. Bufalari A, Giustozzi G, Moggi L. Postoperative intra-abdominal abscesses: Percutaneous versus surgical treatment. Acta Chir Belg 1996, 96(5):197-200.
38. VanSonnenberg E, Mueller PR, Ferrucci JT. Percutaneous drainage of 250 abdominal abscesses and fluid collections. I. Results, failures, and complications. Radiology 1984, 151:337-341.
39. Jaffe TA, Nelson RC, DeLong D, Paulson EK. Practice Patterns in Percutaneous Image-guided Intra-abdominal Abscess Drainage: Survey of Academic and Private Practice Centres. Radiology 2004, 233(3):750-6. 10.1148/radiol.2333032063, 15516608.
40. Lang EK, Springer RM, Glorioso LW, Cammarata CA. Abdominal abscess drainage under radiologic guidance: Causes of failure. Radiology 1986, 159:329-336.
41. Mason RJ. Surgery for appendicitis: is it necessary?. Surg Infect (Larchmt) 2008, 9(4):481-488. 10.1089/sur.2007.079, 18687030.
42. Eriksson S, Granström L. Randomized controlled trial of appendicectomy versus antibiotic therapy for acute appendicitis. Br J Surg 1995, 82(2):166-169. 10.1002/bjs.1800820207, 7749676.
43. Styrud J, Eriksson S, Nilsson I, Ahlberg G, Haapaniemi S, Neovius G, Rex L, Badume I, Granström L. Appendectomy versus antibiotic treatment in acute appendicitis. a prospective multicentre randomized controlled trial. World J Surg 2006, 30(6):1033-1037. 10.1007/s00268-005-0304-6, 16736333.
44. Hansson J, Körner U, Khorram-Manesh A, Solberg A, Lundholm K. Randomized clinical trial of antibiotic therapy versus appendicectomy as primary treatment of acute appendicitis in unselected patients. Br J Surg 2009, 96(5):473-481. 10.1002/bjs.6482, 19358184.
45. Bennett J, Boddy A, Rhodes M. Choice of approach for appendicectomy: A meta-analysis of open versus laparoscopic appendicectomy. Surg Laparosc Endosc 2007, 17:245-255.
46. Corfield L. Interval appendicectomy after appendiceal mass or abscess in adults: What is "best practice"?. Surg Today 2007, 37(1):1-4. 10.1007/s00595-006-3334-2, 17186336.
47. Andersson RE, Petzold MG. Nonsurgical treatment of appendiceal abscess or phlegmon: A systematic review and meta-analysis. Ann Surg 2007, 246(5):741-748. 10.1097/SLA.0b013e31811f3f9f, 17968164.
48. Deakin DE, Ahmed I. Interval appendicectomy after resolution of adult inflammatory appendix mass--is it necessary?. Surgeon 2007, 5(1):45-50. 10.1016/S1479-666X(07)80111-9, 17313128.
49. Golfieri R, Cappelli A. Computed tomography-guided percutaneous abscess drainage in coloproctology: Review of the literature. Tech Coloproctol 2007, 11:197-208. 10.1007/s10151-007-0354-x, 17676271.
50. Ambrosetti P, Chautems R, Soravia C, Peiris-Waser N, Terrier F. Long-term outcome of mesocolic and pelvic diverticular abscesses of the left colon: A prospective study of 73 cases. Dis Colon Rectum 2005, 48(4):787-791. 10.1007/s10350-004-0853-z, 15747071.
51. Brandt D, Gervaz P, Durmishi Y, Platon A, Morel P, Poletti PA. Percutaneous CT scan-guided drainage vs. antibiotherapy alone for Hinchey II diverticulitis: A case-control study. Dis Colon Rectum 2006, 49(10):1533-1538. 10.1007/s10350-006-0613-3, 16988856.
52. Siewert B, Tye G, Kruskal J, Sosna J, Opelka F, Raptopoulos V, Goldberg SN. Impact of CT-guided drainage in the treatment of diverticular abscesses: size matters. AJR Am J Roentgenol 2006, 186(3):680-6. 10.2214/AJR.04.1708, 16498095.
53. McCafferty MH, Roth L, Jorden J. Current management of diverticulitis. Am Surg 2008, 74(11):1041-1049.
54. Salem L, Flum DR. Primary anastomosis or Hartmann's procedure for patients with diverticular peritonitis? A systematic review. Dis Colon Rectum 2004, 47(11):1953-1964. 10.1007/s10350-004-0701-1, 15622591.
55. Chandra V, Nelson H, Larson DR, Harrington JR. Impact of primary resection on the outcome of patients with perforated diverticulitis. Arch Surg 2004, 139(11):1221-1224. 10.1001/archsurg.139.11.1221, 15545570.
56. Constantinides VA, Tekkis PP, Athanasiou T, Aziz O, Purkayastha S, Remzi FH, Fazio VW, Aydin N, Darzi A, Senapati A. Primary resection with anastomosis vs. Hartmann's procedure in nonelective surgery for acute colonic diverticulitis: A systematic review. Dis Colon Rectum 2006, 49(7):966-981. 10.1007/s10350-006-0547-9, 16752192.
57. Titu LV, Zafar N, Phillips SM, Greenslade GL, Dixon AR. Emergency laparoscopic surgery for complicated diverticular disease. Colorectal Dis 2009, 11(4):401-404. 10.1111/j.1463-1318.2008.01606.x, 18616737.
58. Zapletal C, Woeste G, Bechstein WO, Wullstein C. Laparoscopic sigmoid resections for diverticulitis complicated by abscesses or fistulas. Int J Colorectal Dis 2007, 22(12):1515-1521. 10.1007/s00384-007-0359-y, 17646998.
59. Klarenbeek BR, Veenhof AA, Bergamaschi R, Peet DL, Broek WT, de Lange ES, Bemelman WA, Heres P, Lacy AM, Engel AF, Cuesta MA. Laparoscopic sigmoid resection for diverticulitis decreases major morbidity rates: A randomized control trial: Short-term results of the Sigma Trial. Ann Surg 2009, 249(1):39-44. 10.1097/SLA.0b013e31818e416a, 19106674.
60. Toorenvliet BR, Swank H, Schoones JW, Hamming JF, Bemelman WA. Laparoscopic peritoneal lavage for perforated colonic diverticulitis: A systematic review. Colorectal Dis 2009,
61. Alamili M, Gögenur I, Rosenberg J. Acute complicated diverticulitis managed by laparoscopic lavage. Dis Colon Rectum 2009, 52(7):1345-1349.
62. Sauerlenad S, Agresta F, Bergamaschi R, Borzellino G, Budzynsky A, Champault G, Fingerhut A, Isla A, Johansson M, Lundorff P, Navez B, Saad S, Neugebauer EA. Laparoscopic for abdominal emergencies: Evidence based guidelines of the European Association for Endoscopic Surgery. Surg Endosc 2006, 20(1):14-29. 10.1007/s00464-005-0564-0, 16247571.
63. Sanabria AE, Morales CH, Villegas MI. Laparoscopic repair for perforated peptic ulcer disease. Cochrane Database Syst Rev 2005, 19(4):CD004778.
64. Ergul E, Gozetlik EO. Emergency spontaneous gastric perforations: ulcus versus cancer. Langenbecks Arch Surg 2009, 394(4):643-6446. 10.1007/s00423-008-0331-5, 18418626.
65. Ghosheh B, Salameh JR. Laparoscopic approach to acute small bowel obstruction: review of 1061 cases. Surg Endosc 2007, 21(11):1945-9. Epub 2007 Sep 19, 10.1007/s00464-007-9575-3, 17879114.
66. Gupta S, Kaushik R. Peritonitis - the Eastern experience. World J Emerg Surg 2006, 26(1):13.
67. Afridi SP, Malik F, Ur-Rahman S, Shamim S, Samo KA. Spectrum of perforation peritonitis in Pakistan: 300 cases Eastern experience. World J Emerg Surg 2008, 3:31. 10.1186/1749-7922-3-31, 2614978, 18992164.
68. Ara C, Sogutlu G, Yildiz R, Kocak O, Isik B, Yilmaz S, Kirimlioglu V. Spontaneous small bowel perforations due to intestinal tuberculosis should not be repaired by simple closure. J Gastrointest Surg 2005, 9(4):514-7. 10.1016/j.gassur.2004.09.034, 15797233.
69. Lau H, Lo CY, Patil NG, Yuen WK. Early versus delayed-interval laparoscopic cholecystectomy for acute cholecystitis. A meta-analysis. Surg Endosc 2006, 20(1):82-87. 10.1007/s00464-005-0100-2, 16247580.
70. Papi C, Catarci M, D'Ambrosio L, Gili L, Koch M, Grassi GB, Capurso L. Timing of cholecystectomy for acute cholecystitis: A meta-analysis. Am J Gastroenterol 2004, 99(1):147-155. 10.1046/j.1572-0241.2003.04002.x, 14687156.
71. Gurusamy KS, Samraj K. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Cochrane Database Syst Rev 2006, 18(4):CD005440.
72. Shikata S, Noguchi Y, Fukui T. Early versus delayed cholecystectomy for acute cholecystitis: A meta-analysis of randomized controlled trials. Surg Today 2005, 35(7):553-560. 10.1007/s00595-005-2998-3, 15976952.
73. González-Rodríguez FJ, Paredes-Cotoré JP, Pontón C, Rojo Y, Flores E, Luis-Calo ES, Barreiro-Morandeira F, Punal JA, Fernández A, Paulos A, Santos F, Cainzos M. Early or delayed laparoscopic cholecystectomy in acute cholecystitis? Conclusions of a controlled trial. Hepatogastroenterology 2009, 56(89):11-6.
74. Casillas RA, Yegiyants S, Collins JC. Early laparoscopic cholecystectomy is the preferred management of acute cholecystitis. Arch Surg 2008, 143(6):533-537. 10.1001/archsurg.143.6.533, 18559744.
75. Van Ruler O, Lamme B, de Vos R, Obertop H, Reitsma JB, Boermeester MA. Decision making for relaparotomy in secondary peritonitis. Dig Surg 2008, 25(5):339-346. 10.1159/000158911, 18827489.
76. Hinsdale JG, Jaffe BM. Re-operation for intra-abdominal sepsis. Indications and results in modern critical care setting. Ann Surg 1984, 199(1):31-36. 10.1097/00000658-198401000-00006, 1353254, 6691729.
77. Hutchins RR, Gunning MP, Lucas DN, Allen-Mersh TG, Soni NC. Relaparotomy for suspected intraperitoneal sepsis after abdominal surgery. World J Surg 2004, 28(2):137-141. 10.1007/s00268-003-7067-8, 14708056.
78. Van Ruler O, Lamme B, Gouma DJ, Reitsma JB, Boermeester MA. Variables associated with positive findings at relaparotomy in patients with secondary peritonitis. Crit Care Med 2007, 35(2):468-476. 10.1097/01.CCM.0000253399.03545.2D, 17205025.
79. Holzheimer RG, Gathof B. Re-operation for complicated secondary peritonitis-how to identify patients at risk for persistent sepsis. Eur J Med Res 2003, 8(3):125-134.
80. Lamme B, Mahler CW, van Ruler O, Gouma DJ, Reitsma JB, Boermeester MA. Clinical predictors of ongoing infection in secondary peritonitis: Systematic review. World J Surg 2006, 30(12):2170-2181. 10.1007/s00268-005-0333-1, 17102920.
81. Novotny AR, Emmanuel K, Hueser N, Knebel C, Kriner M, Ulm K, Bartels H, Siewert JR, Holzmann B. Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis. Surgery 2009, 145(1):20-6. 10.1016/j.surg.2008.08.009, 19081471.
82. Dietmar H, Wittmann MD, Gaby A, Iskander MD. The compartment syndrome of the abdominal cavity: A state of the art. Review. Journal of Intensive Care Medicine 2000, 15(4):201-220.
83. Duff JH, Moffat J. Abdominal sepsis managed by leaving abdomen open. Surgery 1981, 90:774-778.
84. Wittmann DH, Aprahamian C, Bergstein JM. Etappenlavage: Advanced diffuse peritonitis managed by planned multiple laparotomies utilizing zippers, slide fastener, and Velcro analogue for temporary abdominal closure. World J Surg 1990, 14:218-226. 10.1007/BF01664876, 2183485.
85. Schein M, Assalia A. The role of planned reoperations and laparostomy in severe intra-abdominal infection: Is a prospective randomized trial possible?. Theor Surg 1994, 9:38-42.
86. Schein M, Saadia R, Jamieson JR, Decker GAG. The 'sandwich technique' in the management of the open abdomen. Br J Surg 1986, 73:369-370. 10.1002/bjs.1800730514, 3708284.
87. Barker DE, Kaufman HJ, Smith LA, Ciraulo DL, Richart CL, Burns RP. Vacuum pack technique of temporary abdominal closure: A 7-year experience with 112 patients. J trauma 2000, 48:201-206. 10.1097/00005373-200002000-00001, 10697075.
88. Miller P, Meredith JW, Johnson JC, Chang MC. Prospective evaluation of vacuum-assisted fascial closure after open abdomen: Planned ventral hernia rate is substantially reduced. Ann Surg 2004, 239:608-614. 10.1097/01.sla.0000124291.09032.bf, 1356268, 15082964.
89. Perez D, Wildi S, Demartines N, Bramkamp M, Koehler C, Clavien PA. Prospective evaluation of vacuum-assisted closure in abdominal compartment syndrome and severe abdominal sepsis. J Am Coll Surg 2007, 205:586-592. 10.1016/j.jamcollsurg.2007.05.015, 17903734.
90. Barker DE, Green JM, Maxwell RA, Smith PW, Mejia VA, Dart BW, Cofer JB, Roe SM, Burns RP. Experience with vacuum-pack temporary abdominal wound closure in 258 trauma and general and vascular surgical patients. J Am Coll Surg 2007, 204:784-792. 10.1016/j.jamcollsurg.2006.12.039, 17481484.
91. Schein M. Planned reoperations and open management in critical intra-abdominal infections: prospective experience in 52 cases. World J Surg 1991, 15:537-545. 10.1007/BF01675658, 1832509.
92. Adkins AL, Robbins J, Villalba M, Bendick P, Shanley CJ. Open abdomen management of intra-abdominal sepsis. Am Surg 2004, 70:137-140.
93. Jansen JO, Loudon MA. Damage control surgery in a non-trauma setting. Br J Surg 2007, 94(7):789-90. 10.1002/bjs.5922, 17571297.
94. Wild T, Stortecky S, Stremitzer S, Lechner P, Humpel G, Glaser K, Fortelny R, Karner J, Sautner T. [Abdominal dressing -- a new standard in therapy of the open abdomen following secondary peritonitis?]. Zentralbl Chir 2006, 131(Suppl 1):S111-114. 10.1055/s-2006-921490, 16575659.
95. Zügel N, Siebeck M, Geissler B, Lichtwark-Aschoff M, Gippner-Steppert C, Witte J, Jochum M. Circulating mediators and organ function in patients undergoing planned relaparotomy vs conventional surgical therapy in severe secondary peritonitis. Arch Surg 2002, 137(5):590-599. 10.1001/archsurg.137.5.590, 11982474.
96. Lamme B, Boermeester MA, Belt EJ, van Till JW, Gouma DJ, Obertop H. Mortality and morbidity of planned relaparotomy versus relaparotomy on demand for secondary peritonitis. Br J Surg 2004, 91:1046-1054. 10.1002/bjs.4517, 15286969.
97. Hau T, Ohmann C, Wolmershauser A, Lichtwark-Aschoff M, Gippner-Steppert C, Witte J, Jochum M. Planned relaparotomy vs relaparotomy on demand in the treatment of intraabdominal infections. The Peritonitis Study Group of the Surgical Infection Society-Europe. Arch Surg 1995, 130:1193.
98. Van Ruler O, Mahler CW, Boer KR, Reuland EA, Gooszen HG, Opmeer BC, de Graaf PW, Lamme B, Gerhards MF, Steller EP, van Till JW, de Borgie CJ, Gouma DJ, Reitsma JB, Boermeester MA. Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: A randomized trial. JAMA 2007, 298:865-872. 10.1001/jama.298.8.865, 17712070.
99. Robledo FA, Luque-de-León E, Suárez R, Sánchez P, de-la-Fuente M, Vargas A, Mier J. Open versus closed management of the abdomen in the surgical treatment of severe secondary peritonitis: a randomized clinical trial. Surg Infect (Larchmt) 2007, 8:63-72. 10.1089/sur.2006.8.016, 17381398.
100. Gladman MA, Knowles CH, Gladman LJ, Payne JG. Intra-operative culture in appendicitis: Traditional practice challenged. Ann R Coll Surg Engl 2004, 86(3):196-201. 10.1308/003588404323043346, 1964168, 15140306.
101. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow AW, Bartlett J, . Infectious Diseases Society of America Infectious Diseases Society of America: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003, 15,37(8):997-1005. Infectious Diseases Society of America.
102. Weigelt JA. Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med 2007, 74(Suppl 4):S29-37. 10.3949/ccjm.74.Suppl_4.S29, 17847176.
103. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010, 50(2):133-64. 10.1086/649554, 20034345.
104. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, Dupont H. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009, 63(4):785-94. 10.1093/jac/dkp005, 19196742.
105. Seguin P, Laviolle B, Chanavaz C, Donnio PY, Gautier-Lerestif AL, Campion JP, Mallédant Y. Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 2006, 12(10):980-5. 10.1111/j.1469-0691.2006.01507.x, 16961634.
106. Swenson BR, Metzger R, Hedrick TL, McElearney ST, Evans HL, Smith RL, Chong TW, Popovsky KA, Pruett TL, Sawyer RG. Choosing antibiotics for intra-abdominal infections: What do we mean by "high risk"?. Surg Infect (Larchmt) 2009, 10(1):29-39. 10.1089/sur.2007.041, 19226202.
107. Powell LL, Wilson SE. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect (Larchmt) 2000, 1(1):57-63. 10.1089/109629600321308, 12594910.
108. Lode HM. Rational antibiotic therapy and the position of ampicillin/sulbactam. Int J Antimicrob Agents 2008, 32(1):10-28. 10.1016/j.ijantimicag.2008.02.004, 18539004.
109. Betrosian AP, Douzinas EE. Ampicillin-sulbactam: An update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol 2009, 5(9):1099-1112. 10.1517/17425250903145251, 19621991.
110. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: A population-based study, 1998-2007. J Antimicrob Chemother 2009, 64(1):169-174. 10.1093/jac/dkp162, 19435736.
111. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: A beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007, 5(3):365-383. 10.1586/14787210.5.3.365, 17547502.
112. Hammond ML. Ertapenem: A Group 1 carbapenem with distinct antibacterial and pharmacological properties. J Antimicrob Chemother 2004, 53(Suppl 2):ii7-9. 10.1093/jac/dkh203, 15150178.
113. Falagas ME, Peppas G, Makris GC, Karageorgopoulos DE, Matthaiou DK. Meta-analysis: Ertapenem for complicated intra-abdominal infections. Aliment Pharmacol Ther 2008, 27(10):919-931.
114. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S- a new carbapenem. Antimicrob Agents Chemother 4661, 42(1):94-99.
115. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. Journal of Antimicrobial Chemotherapy 2004, 54(1):144-154. 10.1093/jac/dkh298, 15190031.
116. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: Tentative disc diffusion criteria and quality control. Journal of Antimicrobial Chemotherapy 2005, 55(6):944-949. 10.1093/jac/dki134, 15872043.
117. Sahm D. In vitro activity of doripenem. Clin Infect Dis 2009, 49(Suppl 1):S11-6. 10.1086/599811, 19619017.
118. Powell LL, Wilson SE. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect (Larchmt) 2000, 1(1):57-63. 10.1089/109629600321308, 12594910.
119. Paterson DL, Bonomo RA. Extended-Spectrum β-Lactamases: A Clinical Update. Clin Microbiol Rev 2005, 18(4):657-686. 10.1128/CMR.18.4.657-686.2005, 1265908, 16223952.
120. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 2006, 34(5 Suppl 1):S20-8. 10.1016/j.ajic.2006.05.238, 16813978.
121. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990, 3:45-65.
122. Garbino J, Villiger P, Caviezel A, Matulionyte R, Uckay I, Morel P, Lew D. A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections. Infection 2007, 35(3):161-166. 10.1007/s15010-007-6237-2, 17565457.
123. Endimiani A, Perez F, Bonomo RA. Cefepime: A reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther 2008, 6(6):805-824. 10.1586/14787210.6.6.805, 2633657, 19053894.
124. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: A systematic review and meta-analysis. Lancet Infect Dis 2007, 7(5):338-348. 10.1016/S1473-3099(07)70109-3, 17448937.
125. Drago L, De Vecchi E. The safety of cefepime in the treatment of infection. Expert Opin Drug Saf 2008, 7(4):377-387. 10.1517/14740338.7.4.377, 18613802.
126. Borcherding SM, Stevens R, Nicholas RA, Corley CR, Self T. Quinolones: A practical review of clinical uses, dosing considerations, and drug interactions. J Fam Pract 1996, 42:69-78.
127. Falagas ME, Matthaiou DK, Bliziotis IA. Systematic review: Fluoroquinolones for the treatment of intra-abdominal surgical infections. Aliment Pharmacol Ther 2007, 25(2):123-131.
128. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008, 20;13(47).
129. Weiss G, Reimnitz P, Hampel B, Muehlhofer E, Lippert H, . AIDA Study Group Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother 2009, 21(2):170-180. AIDA Study Group.
130. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996, 23(suppl 1):S19-24.
131. Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, Towne JB. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004, 48(3):1012-1016. 10.1128/AAC.48.3.1012-1016.2004, 353113, 14982797.
132. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez H. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006, 50(1):148-155. 10.1128/AAC.50.1.148-155.2006, 1346786, 16377680.
133. Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B. DRAGON Study Team. Int J Antimicrob Agents 2009, 34(5):439-445. 10.1016/j.ijantimicag.2009.06.022, 19692210.
134. Lemmen SW, Häfner H, Klik S, Lütticken R, Zolldann D. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. Chemotherapy 2003, 49(1-2):33-35. 10.1159/000069779, 12714807.
135. Marchetti F, Viale P. Current and future perspectives for levofloxacin in severe Pseudomonas aeruginosa infections. J Chemother 2003, 15(4):315-322.
136. Neu HC. Aztreonam activity, pharmacology, and clinical uses. Am J Med 1990, 23;88(3C):2S-6S.
137. Malangoni MA. Aztreonam in treatment of intra-abdominal infections. Urology 1988, 31(6 Suppl):28-32.
138. Bradford PA. Tigecycline: A first in class glycylcycline. Clin Microbiol Newsl 2004, 26:163-168.
139. Townsend ML, Pound MW, Drew RH. Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections. Ther Clin Risk Manag 2007, 3(6):1059-1070. 2387284, 18516315.
140. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000, 44:2225-2229. 10.1128/AAC.44.8.2225-2229.2000, 90048, 10898710.
141. Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, . Hellenic Tigecycline Study Group In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints. Diagn Microbiol Infect Dis 2010, 66(2):187-194. 10.1016/j.diagmicrobio.2009.09.012, 19836184, Hellenic Tigecycline Study Group.
142. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: What are the treatment options?. Drugs 2009, 69(14):1879-1901. 10.2165/11315690-000000000-00000, 19747006.
143. Mezzatesta ML, Trovato G, Gona F, Nicolosi VM, Nicolosi D, Carattoli A, Fadda G, Nicoletti G, Stefani S. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann Clin Microbiol Antimicrob 2008, 7:4. 10.1186/1476-0711-7-4, 2275293, 18261233.
144. Curcio D, Fernandez F. Acinetobacter spp. susceptibility to tigecycline: A worldwide perspective. J Antimicrob Chemother 2007, 60:449-450. 10.1093/jac/dkm202, 17561503.
145. Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51:1621-1626. 10.1128/AAC.01099-06, 1855572, 17307973.
146. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S12-8. 10.1086/521863, 18177217.
147. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients. A randomized trial. Am J Respir Crit Care Med 2008, 177:498-505. 10.1164/rccm.200708-1238OC, 18096708.
148. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, Schroeder S. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: A randomized prospective controlled trial. Crit Care 2009, 13(3):R83. 10.1186/cc7903, 2717450, 19493352.
149. Tellado JM, Sitges-Serra A, Barcenilla F, Palomar M, Serrano R, Barberán J, Moya M, Martínez M, García-Rodríguez JA, Mensa J, Prieto J. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain.
150. Edelsberg J, Berger A, Schell S, Mallick R, Kuznik A, Oster G. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt) 2008, 9(3):335-347. 10.1089/sur.2006.100, 18570575.
151. Höffken G, Niederman M. Nosocomial pneumonia. The importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002, 122:2183-96. 10.1378/chest.122.6.2183, 12475862.
152. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004, 32:2183-90.
153. Linden PK. Optimizing therapy for vancomycin-resistant Enterococci (VRE). Semin Respir Crit Care Med 2007, 28:632-645. 10.1055/s-2007-996410, 18095227.
154. Chou YY, Lin TY, Lin JC, Wang NC, Peng MY, Chang FY. Vancomycin-resistant enterococcal bacteremia: Comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis. J Microbiol Immunol Infect 2008, 41(2):124-129.
155. Jean SS, Fang CT, Wang HK, Hsueh PR, Chang SC, Luh KT. Invasive infections due to vancomycin-resistant Enterococci in adult patients. J Microbiol Immunol Infect 2001, 34:281-286.
156. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant Enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003, 24:251-256. 10.1086/502196, 12725353.
157. Noskin GA. Vancomycin-resistant Enterococci: Clinical, microbiologic, and epidemiologic features. J Lab Clin Med 1997, 130:14-20. 10.1016/S0022-2143(97)90054-8, 9242362.
158. Mazuski JE. Vancomycin-resistant Enterococcus: Risk factors, surveillance, infections, and treatment. Surg Infect (Larchmt) 2008, 9(6):567-571. 10.1089/sur.2008.9955, 19216668.
159. Sitges-serra A, Lopez M, Girvent M, Almirall S, Sancho J. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002, 89:361-367. 10.1046/j.0007-1323.2001.02023.x, 11872065.
160. Harbarth S, Uckay I. Are there patients with peritonitis who require empiric therapy for Enterococcus?. Eur J Clin Microbiol Infect Dis 2004, 23(2):73-77. 10.1007/s10096-003-1078-0, 14735401.
161. Riché FC, Dray X, Laisné MJ, Matéo J, Raskine L, Sanson-Le Pors MJ, Payen D, Valleur P, Cholley BP. Factors associated with septic shock and mortality in generalized peritonitis: Comparison between community-acquired and postoperative peritonitis. Crit Care 2009, 13(3):R99. 10.1186/cc7931, 2717471, 19552799.
162. Mazuski JE. Antimicrobial treatment for intra-abdominal infections. Expert Opin Pharmacother 2007, 8(17):2933-45. 10.1517/14656566.8.17.2933, 18001254.
163. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005, 65(12):1611-20. 10.2165/00003495-200565120-00002, 16060697.
164. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, Martone WJ. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992, 13:582-586. 10.1086/646432, 1469266.
165. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005, 41:S269-272. 10.1086/430788, 16032563.
166. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003, 52:864-868. 10.1093/jac/dkg457, 14563898.
167. Cunha BA. Methicillin-resistant Staphylococcus aureus: Clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 2005, 11(Suppl 4):33-42. 10.1111/j.1469-0691.2005.01162.x, 15997484.
168. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999, 20:303-316. 10.1016/S0272-5231(05)70143-X, 10386258.
169. Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods JL, Satishchandran V, Snyder TA, Harvey CM, Teppler H, Dinubile MJ, Chow JW. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 study for monitoring antimicrobial resistance trends (SMART). J Antimicrob Chemother 2005, 55:965-973. 10.1093/jac/dki117, 15849262.
170. Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV, Snyder TA, Satishchandran V, McCarroll K, DiNubile MJ, Chow JW. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006, 58:205-210. 10.1093/jac/dkl199, 16717055.
171. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis 2006, 42(Suppl 4):S153-63. 10.1086/500662, 16544266.
172. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006, 119:S3-10. 10.1016/j.amjmed.2006.03.011, 16735149.
173. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis 2006, 56:367-72. 10.1016/j.diagmicrobio.2006.07.004, 17020798.
174. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: Results from the SMART study. Int J Antimicrob Agents 2009, 34(6):585-588. 10.1016/j.ijantimicag.2009.07.013, 19748234.
175. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial Gram-negative bacilli in the United States. J Infect Dis 1994, 170:1622-5.
176. Quinn JP, Dudek EJ, Di Vincenzo CA, DiVincenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 1986, 154:289-294.
177. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: What are the treatment options?. Drugs 2009, 69(14):1879-1901. 10.2165/11315690-000000000-00000, 19747006.
178. Lin WJ, Lo WT, Chu CC, Chu ML, Wang CC. Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infection in children. J Microbiol Immunol Infect 2006, 39:249-254.
179. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003, 36(10):1268-1274. 10.1086/374847, 12746772.
180. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000, 31(3):690-697. 10.1086/314040, 11017817.
181. Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, Flores C, Brooks S. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: The pre-antibiotic era has returned. Arch Intern Med 2002, 162(13):1515-1520. 10.1001/archinte.162.13.1515, 12090889.
182. Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, García-Garmendía JL, Ortiz C, Cobacho AR. Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996, 22:1026-1032.
183. Humphreys H, Towner KJ. Impact of Acinetobacter spp. in intensive care units in Great Britain and Ireland. J Hosp Infect 1997, 37:281-286. 10.1016/S0195-6701(97)90144-4, 9457605.
184. Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004, 10:684-704. 10.1111/j.1469-0691.2004.00942.x, 15301671.
185. Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009, 34(2):121-30. Epub 2009 Apr 1, 10.1016/j.ijantimicag.2009.02.003, 19342205.
186. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999, 28(5):1008-1011. 10.1086/514732, 10452626.
187. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001, 40(3):117-120. 10.1016/S0732-8893(01)00258-9, 11502379.
188. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: Citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000, 31(1):101-106. 10.1086/313902, 10913404.
189. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004, 48(5):1586-1592. 10.1128/AAC.48.5.1586-1592.2004, 400525, 15105109.
190. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004, 48(3):753-757. 10.1128/AAC.48.3.753-757.2004, 353107, 14982760.
191. Pumbwe L, Wareham DW, Aduse-Opoku J, Brazier JS, Wexler HM. Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of Bacteroides fragilis. Clin Microbiol Infect 2007, 13:183-189. 10.1111/j.1469-0691.2006.01620.x, 17328731.
192. Wareham DW, Wilks M, Ahmed D, Brazier JS, Millar M. Anaerobic sepsis due to multidrug-resistant Bacteroides fragilis: microbiological cure and clinical response with linezolid therapy. Clin Infect Dis 2005, 40:67-68. 10.1086/428623, 15614694.
193. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007, 51:1649-1655. 10.1128/AAC.01435-06, 1855532, 17283189.
194. Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001, 45(4):1238-1243. 10.1128/AAC.45.4.1238-1243.2001, 90449, 11257040.
195. Blot SI, Vandewoude KH, De Waele JJ. Candida peritonitis. Curr Opin Crit Care 2007, 13(2):195-199. 10.1097/MCC.0b013e328028fd92, 17327742.
196. Senn L, Eggimann P, Ksontini R, Pascual A, Demartines N, Bille J, Calandra T, Marchetti O. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 2009, 35(5):903-908. 10.1007/s00134-009-1405-8, 19172247.
197. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, . Infectious Diseases Society of America Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 1;48(5):503-35. Infectious Diseases Society of America.
198. Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 2001, 5(4):189-95. Epub 2001 Jun 28, 10.1186/cc1022, 137278, 11511331.